<div id="readability-page-1"><p>Danaher, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tycho Peterson from Jefferies maintained a Buy rating on the stock and has a $265.00 price target.</p><div><p>Tycho Peterson has given his Buy rating due to a combination of factors that indicate a constructive outlook for Danaher’s growth and profitability into 2026. The company’s fourth-quarter results were solid versus expectations, with particular strength in bioprocessing consumables and key diagnostics franchises, underscoring the resilience of its core healthcare and life sciences portfolio. Management’s 2026 guidance, calling for mid‑single‑digit core growth and high‑single‑digit EPS expansion, is viewed as achievable, with a deliberate under‑promise/over‑deliver setup supported by easing comparisons in the back half of the year and the timing of cost savings.</p><p>  Peterson also highlights bioprocessing and life sciences as key upside levers that could push growth and earnings above the baseline outlook. In bioprocessing, stabilizing equipment demand, improving order trends, and healthy consumables tied to biologics, biosimilars, and mAbs provide a clear path to high‑single‑digit growth, with additional optionality from greenfield and reshoring projects. In life sciences, any recovery in U.S. academic/government spending, biotech funding translating into orders, and a rebound in China research could lift segment performance above current assumptions. Coupled with a more supportive M&amp;A environment and a valuation that already reflects conservative expectations, these factors collectively underpin Peterson’s Buy recommendation on Danaher. </p></div><p>Peterson covers the Healthcare sector, focusing on stocks such as Merck &amp; Company, Qiagen, and Danaher. According to TipRanks, Peterson has an average return of <span>9.9%</span> and a 59.09% success rate on recommended stocks.</p></div>

SBIO

<p>Danaher has received a Buy rating from Jefferies analyst Tycho Peterson, who set a price target of $265.00. The positive outlook is based on solid fourth-quarter results, particularly in bioprocessing and diagnostics. Management's guidance for mid-single-digit core growth and high-single-digit EPS expansion is deemed achievable. Key growth drivers include stabilizing demand in bioprocessing and potential recovery in life sciences spending. Peterson's analysis suggests that these factors, along with a favorable M&A environment, support the Buy recommendation for Danaher.</p>

- Analysts on Wall Street have reassessed Danaher in the healthcare sector, with Jefferies' Tycho Peterson maintaining a "buy" rating and setting a target price of $265.00.  
- Peterson cites solid fourth-quarter performance, particularly in bioprocessing consumables and core diagnostics, indicating positive growth and profitability prospects for 2026.  
- He highlights the resilience of Danaher’s healthcare and life sciences portfolio, supported by stable equipment demand and potential growth drivers in bioprocessing and life sciences.

Tip Ranks

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Danaher

Proshares Ultra Nasdaq Biotech

iShares US Medical Devices

VanEck Biotech ETF

SPDR S&P Health Equip

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Danaher: Solid Core Performance and Bioprocessing Upside Support Buy Rating into 2026